• Users Online: 1291
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2021  |  Volume : 7  |  Issue : 2  |  Page : 84-87

Lenalidomide in a case of thalidomide intolerant erythema nodosum leprosum

Department of Dermatology, INHS Asvini, Mumbai, Maharashtra, India

Correspondence Address:
Jandhyala Sridhar
Department of Dermatology, INHS Asvini, Colaba, Mumbai 400005, Maharashtra.
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijdd.ijdd_50_20

Rights and Permissions

Lenalidomide is an immunomodulatory drug, which is considered to be a derivative of thalidomide. It has a more potent suppressive effect on tumor necrosis factor-α (TNF-α) production and has a more tolerable adverse effect profile as compared to its parent drug. It has been approved by FDA for use in multiple hematopoietic malignancies and myelodysplasia, but unlike thalidomide its use in erythema nodosum leprosum (ENL) has not been reported so far. Herein we report a case of 45-year-old man with Hansen’s disease (BL) on MDT for 4 months who presented with ENL and was managed with minimum dose of lenalidomide.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded33    
    Comments [Add]    

Recommend this journal